• Molecular NameSulfasalazine
  • SynonymSulfasalazin; Sulphasalazine
  • Weight398.399
  • Drugbank_IDDB00795
  • ACS_NO599-79-1
  • Show 2D model
  • LogP (experiment)3.8
  • LogP (predicted, AB/LogP v2.0)3.69
  • pka0.6, 2.4, 9.7, 11.8
  • LogD (pH=7, predicted)-0.4
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-2.15
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.09
  • No.of HBond Donors3
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds6
  • TPSA149.69
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn anti-inflammatory agent in the treatment of inflammatory bowel disease as well as for rheumatoid arthritis.
  • Absorption_value13.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding99.3
  • Volume of distribution (VD)0.1 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmFollowing oral administration of 1 g of Sulfasalazine to 9 healthy males, less than 15% of a dose of Sulfasalazine is absorbed as parent drug. In the intestine, Sulfasalazine is metabolized by intestinal bacteria to sulfapyridine (SP) and 5-aminosalycilic acid (5-ASA)
  • Half life10 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityThe most common adverse reactions associated with sulfasalazine in ulcerative colitis are anorexia, headache, nausea, vomiting, gastric distress, and apparently reversible oligospermia.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A